Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 March;63(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 March;63(1):29-36

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW  PROSTATE CANCER 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2019 March;63(1):29-36

DOI: 10.23736/S1824-4785.19.03155-8

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Prostate-specific membrane antigen radioligand therapy of prostate cancer

Mohsen BEHESHTI 1, 2, Alexander HEINZEL 1, Dirk von MALLEK 1, Christian FILSS 1, Felix M. MOTTAGHY 1, 3

1 Department of Nuclear Medicine, University Hospital, RWTH University, Aachen, Germany; 2 Department of Nuclear Medicine and Endocrinology, Paracelsus Medical University, Salzburg, Austria; 3 Department of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands



Defining an optimal therapeutic approach in metastatic castration-resistance prostate cancer (mCRPC) patients in advanced stages is still challenging in routine clinical practice. Prostate-specific membrane antigen (PSMA) targeted radionuclide therapy with β- or α-emitters such as 177-Lutethium (177Lu) or 225-Actinium (225A) has been a main focus at multiple academic research centers in the last few years. This review article provides an overview of PSMA characteristics, clinical performance, safety and toxicity of PSMA targeted β- or α-radiation therapy.


KEY WORDS: Prostatic neoplasms - 177Lu-PSMA-617 - Radiotherapy

top of page